

Duplicate #10

In the claims:

N.B.

Please cancel claims 2-54 without prejudice, and amend claim 1 as follows:

N.B. (DRAFT)

1. **(Amended)** A method for [modulating] downregulating HIV-1 fusion cofactor expression in a T cell, comprising [manipulating an accessory molecule on the surface of a] contacting the T cell with a CD28 ligand *in vitro*, thereby [modulating] downregulating HIV-1 fusion cofactor expression in the T cell.

Please add new claims 55-86 as follows:

N.B. (DRAFT)

55. A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vitro*, thereby downregulating CCR5 expression in the T cell.

56. The method of claim 55, wherein said T cell is activated.

57. The method of claim 55, wherein said CD28 ligand is an anti-CD28 antibody.

58. The method of claim 57, wherein said anti-CD28 antibody is immobilized on a solid surface.

59. The method of claim 57, wherein said anti-CD28 antibody is soluble.

60. A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating CCR5 expression in the T cell.

61. The method of claim 60, wherein said T cell is activated.

62. The method of claim 60, wherein said CD28 ligand is an anti-CD28 antibody.

63. The method of claim 62, wherein said anti-CD28 antibody is immobilized on a solid surface.

64. The method of claim 62, wherein said anti-CD28 antibody is soluble.

*N.F.
(duplicative)*

65. A method for downregulating CXCR4 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vitro*, thereby downregulating CXCR4 expression in the T cell.

66. The method of claim 65, wherein said T cell is activated.

67. The method of claim 65, wherein said CD28 ligand is an anti-CD28 antibody.

68. The method of claim 67, wherein said anti-CD28 antibody is immobilized on a solid surface.

69. The method of claim 67, wherein said anti-CD28 antibody is soluble.

70. A method for downregulating CXCR4 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating CXCR4 expression in the T cell.

71. The method of claim 70, wherein said T cell is activated.

72. The method of claim 70, wherein said CD28 ligand is an anti-CD28 antibody.

73. The method of claim 72, wherein said anti-CD28 antibody is immobilized on a solid surface.

74. The method of claim 72, wherein said anti-CD28 antibody is soluble.

75. A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating HIV-1 fusion cofactor expression in the T cell.

76. The method of claim 75, wherein said T cell is activated.

77. The method of claim 75, wherein said CD28 ligand is an anti-CD28 antibody.

78. The method of claim 75, wherein said HIV-1 fusion cofactor is CCR5.

79. The method of claim 75, wherein said HIV-1 fusion cofactor is CXCR4.